NVAX

Business Context and Reporting Period

Company: Novavax, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: Novavax is a clinical-stage biopharmaceutical company developing vaccines using its proprietary Virus-Like Particle (VLP) platform. Key product candidates include vaccines for H1N1, seasonal influenza, H5N1 avian influenza, Varicella Zoster (shingles), and Respiratory Syncytial Virus (RSV). The company relies on third-party manufacturing and strategic collaborations for commercialization.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Nine-month revenue decreased 75% to $0.3 million from $1.0 million in the prior year, primarily due to the completion of a National Institutes of Health (NIH) contract.
• Operating Expenses:
  • R&D: Decreased 20% to $14.8 million (nine months) due to the absence of $3.0 million in milestone fees and $0.5 million in lease accruals recorded in the prior year.
  • G&A: Increased 13% to $8.7 million (nine months), largely driven by a $1.0 million credit in the prior year related to the correction of an accounting error regarding notes receivable from former directors.
• Debt Reduction: The company fully extinguished $22 million in senior convertible notes during the period. $17 million was retired in April 2009 (partially via cash and stock issuance), and the remaining $5 million balance was paid in July 2009.
• Discontinued Operations: The company recorded no income from discontinued operations in 2009, compared to $2.5 million in the prior quarter and $0.8 million in the prior nine-month period, following the exit of the Estrasorb manufacturing facility in August 2008.
• Investment Impairment: Recorded a $1.4 million other-than-temporary impairment charge on auction rate securities due to credit market illiquidity, partially offset by $0.7 million in realized gains from the redemption of two securities.

Guidance, Outlook, and Risks

• Product Development:
  • H1N1: Completed production of the first batch within 12 weeks. Announced positive preclinical results in ferrets. Initiated a two-stage clinical trial in Mexico in collaboration with Avimex; primary results expected in January 2010.
  • Seasonal Flu: Announced positive Phase II results meeting FDA seroconversion criteria. Planning a dose-ranging study in the elderly for Q4 2009.
  • RSV & VZV: Selected an RSV candidate for further preclinical studies; received a $246,000 SBIR grant from NIAID. VZV candidate showing positive antibody responses.
• Capital Resources: Management believes current cash ($30.0 million) and short-term investments ($4.4 million) are sufficient to fund operations for the next 12 months. Future capital will be required for clinical development and commercialization.
• Strategic Transactions:
  • Entered into a new At-the-Market (ATM) sales agreement for up to $10 million in September 2009.
  • Executed a binding term sheet with Xcellerex for H1N1 bulk manufacturing for the Mexican market.
  • Negotiating definitive license agreements with ROVI (Spain) for flu vaccine commercialization.
• Risks:
  • Regulatory & Manufacturing: No assurance of regulatory approval for H1N1 in Mexico or the US; reliance on third-party manufacturers (Xcellerex) for commercial scale-up.
  • Market Timing: H1N1 vaccine sales may not begin until late in the 2009/2010 flu season, potentially limiting commercial opportunity.
  • Foreign Operations: Risks associated with collaborations in Mexico (Avimex) and India (Cadila), including regulatory hurdles and political instability.
  • Liquidity: Continued need for equity or debt financing; potential dilution to shareholders.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the ~$34.4 million in liquid assets against the projected burn rate for the next 12 months, considering the high cost of clinical trials.
• H1N1 Timeline: Confirm the status of the Mexican clinical trial and the likelihood of regulatory approval before the end of the 2009/2010 flu season.
• Manufacturing Capacity: Assess the reliability and capacity of the Xcellerex partnership for commercial-scale production.
• ROVI Agreement: Monitor the progress of negotiations with ROVI, as a definitive agreement is critical for European market access.
• Investment Portfolio: Review the valuation and liquidity of the remaining auction rate securities ($4.4 million fair value vs. $5.6 million par value).
• Related Party Transactions: Note the $26.5 million aggregate agreements with Cadila (in which a director has an interest) and the status of the $1.6 million in notes receivable from former directors.